CenExel iResearch

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Depression4 trials
• Bipolar disorder2 trials
• Schizophrenia2 trials
• Fatty liver disease (MASLD/MASH)1 trial
• Obstructive sleep apnoea1 trial

Phase

• Phase 24 trials
• Phase 34 trials

Status

• Active, not recruiting3 trials
• Completed3 trials
• Recruiting2 trials

Lead sponsor

• Xenon Pharmaceuticals Inc.3 trials
• Apnimed1 trial
• Beckley Psytech Limited1 trial
• Eccogene1 trial
• LB Pharmaceuticals Inc.1 trial
• and 1 more

Running trials

• Recruiting

  Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

  NCT07467993· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Kimball Johnson (principal investigator)

• Recruiting

  A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07288138· Phase 2· Eccogene· Source

  Contact: Eccogene Clinical Trials

• Active, not recruiting

  An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

  NCT07217860· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

  NCT07172516· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  NCT06775379· Phase 3· Xenon Pharmaceuticals Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Completed

  Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

  NCT06179108· Phase 2· LB Pharmaceuticals Inc.· Source

• Completed

  BPL-003 Efficacy and Safety in Treatment Resistant Depression

  NCT05870540· Phase 2· Beckley Psytech Limited· Source

• Completed

  Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)

  NCT05811247· Phase 3· Apnimed· Source